Sarcoma: Evaluation of Immunotherapy Using Dendritic Cells

Share this content:
Dendritic cell–based immunotherapy does not improve outcomes for patients with refractory sarcoma.
Dendritic cell–based immunotherapy does not improve outcomes for patients with refractory sarcoma.

Dendritic cell–based immunotherapy does not improve outcomes for patients with refractory sarcoma, according to the results of a phase 1/2 study published in Cancer.1

Relapsed sarcomas are often unresponsive to chemotherapy, limiting treatment options in this patient population. For this study, researchers evaluated whether immunotherapy using dendritic cells, which is active in some cancers, would improve clinical outcomes for patients with refractory sarcoma.

Dendritic cells were pulsed with autologous tumor lysate before injection; 47 courses were administered to 37 enrolled patients. Thirty-five patients were assessed at follow-up. There was only 1 partial response, 6 patients had stable disease, and in 28 patients tumor progression was observed.

The 3-year progression-free survival was only 2.9%; the 3-year overall survival rate was 42.3%. Patients with recurrent tumors had longer median survival than those with metastatic or recurrent and metastatic tumors. There were no serious adverse events associated with dendritic cell treatment.

Interferon-y (IFN-y) and IL-12 levels, which have been shown to activate T lymphocytes, were measured 1 month after dendritic cell injection. Although these serum levels were elevated post-treatment, 80% of patients still had disease progression. This outcome may, however, be due to tumor immunosuppression.

RELATED: Ewing Sarcoma Survivors Require Lifelong Follow-up

The authors concluded that dendritic cell–immunotherapy may be effective prior to disease relapse, potentially avoiding tumor immunosuppression. Further study is warranted.

Reference

  1. Miwa S, Nishida H, Tanzawa Y, et al. Phase 1/2 study of immunotherapy with dendritic cells pulsed with autologous tumor lysate in patients with refractory bone and soft tissue sarcoma. Cancer. 2017 Feb 27. doi: 10.1002/cncr.30606 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters